Clinical Trial Update: Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating SHR3824 as monotherapy for type 2 diabetes, focusing on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SHR3824

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: UNKNOWN